{
  "docId": "019de074-0cc8-70d5-8924-3a1b552a09af",
  "docSlug": "77b0d3b8437e31981ed49d98afb5005f",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 43 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 43,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_messages",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 7,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-0cc8-70d5-8924-3a1b552a09af/6",
  "deckHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af",
  "deckJsonHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af.json",
  "deckAnchorHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.32,
        "x": 0.62,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Acceleration of Regulatory Approvals (FDA and EMA) showing growth from Pre-2000 to 2011-2020",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8284c89-4dad-4a29-91d2-4986a2d50deb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "$236B in antibody sales by 2025 (up from ~$212B in 2021); 49 blockbuster antibodies in 2021 (up from 41 in 2020); 5 best-selling antibodies had ~$66B of sales in 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23154dce-2aaf-4037-9c0a-344533d5bb7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Sources: 2021 Sales of Recombinant Therapeutic Antibodies... (1) Defined as composite success rate...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f33d94a-3429-461d-b9aa-4ba983edf1fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "table",
      "text": "Type of Drug: Small Molecules (7.5%), Antibodies (12.1%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8c9d81e-cc5b-4df0-89c2-6b4e36cb563a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.85,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "HIGHER SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea60d0c8-0a14-4609-a0b9-ba9c58b5b8e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Antibodies and Industry Demand",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84af1bc6-704d-4afc-840a-ef713392db7a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "2f2e755f-f50f-4b7b-aac4-eea2ddfa7c51",
      "evidence": "chart/bar-vertical: Acceleration of Regulatory Approvals (FDA and EMA) showing growth from Pre-2000 to 2011-2020",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "c766311b-baa2-43ba-bf6a-9100a5f81d97",
      "evidence": "list/bullet: $236B in antibody sales by 2025 (up from ~$212B in 2021); 49 blockbuster antibodies in 2021 (up from 41 in 2020); 5 best-selling antibodies had ~$66B of sales in 2021",
      "confidence": 0.8
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2105b1d6-7ef5-4a68-918f-91a8701630e6",
      "evidence": "table/data: Type of Drug: Small Molecules (7.5%), Antibodies (12.1%)",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 3,
      "beatId": "99841cfe-3062-4dd6-9929-6d4679d433de",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 3-6 discuss the industry's need for discovery technology and the limitations of current solutions.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d28165e9-330b-4b4c-9bd6-8826c981bf1a",
      "evidence": "Slides 6-16 imply that not using OmniAb's platform may lead to lower success rates for antibody medicines.",
      "position": 0,
      "objective": "Highlight the consequences of not adopting OmniAb's technology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}